Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach

Abstract Background and Aims Cardiac glycosides (CGs), traditionally used for heart failure, have shown potential as anti‐cancer agents. This study aims to explore their multifaceted mechanisms in cancer cell biology using proteome integral solubility alteration (PISA), focusing on the interaction w...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenjie Qin, Yinhua Deng, Huan Ren, Yanling Liu, Ling Liu, Wenhui Liu, Yuxi Zhao, Chen Li, Zhiling Yang
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.70252
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849761848487837696
author Wenjie Qin
Yinhua Deng
Huan Ren
Yanling Liu
Ling Liu
Wenhui Liu
Yuxi Zhao
Chen Li
Zhiling Yang
author_facet Wenjie Qin
Yinhua Deng
Huan Ren
Yanling Liu
Ling Liu
Wenhui Liu
Yuxi Zhao
Chen Li
Zhiling Yang
author_sort Wenjie Qin
collection DOAJ
description Abstract Background and Aims Cardiac glycosides (CGs), traditionally used for heart failure, have shown potential as anti‐cancer agents. This study aims to explore their multifaceted mechanisms in cancer cell biology using proteome integral solubility alteration (PISA), focusing on the interaction with key proteins implicated in cellular metabolism and mitochondrial function. Methods We conducted lysate‐based and intact‐cell PISA assays on cancer cells treated with CGs (Digoxin, Digitoxin, Ouabain) to analyze protein solubility changes. This was followed by mass spectrometric analysis and bioinformatics to identify differentially soluble proteins (DSPs). Molecular docking simulations were performed to predict protein‐CG interactions. Public data including gene expression changes upon CG treatment were re‐analyzed for validation. Results The PISA assays revealed CGs’ broad‐spectrum interactions, particularly affecting proteins like PKM2, ANXA2, SLC16A1, GOT2 and GLUD1. Molecular docking confirmed stable interactions between CGs and these DSPs. Re‐analysis of public data supported the impact of CGs on cancer metabolism and cell signaling pathways. Conclusion Our findings suggest that CGs could be repurposed for cancer therapy by modulating cellular processes. The PISA data provide insights into the polypharmacological effects of CGs, warranting further exploration of their mechanisms and clinical potential.
format Article
id doaj-art-cc1b17f8297848e1a3b4a1e74fc42a3f
institution DOAJ
issn 2045-7634
language English
publishDate 2024-09-01
publisher Wiley
record_format Article
series Cancer Medicine
spelling doaj-art-cc1b17f8297848e1a3b4a1e74fc42a3f2025-08-20T03:05:53ZengWileyCancer Medicine2045-76342024-09-011318n/an/a10.1002/cam4.70252Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approachWenjie Qin0Yinhua Deng1Huan Ren2Yanling Liu3Ling Liu4Wenhui Liu5Yuxi Zhao6Chen Li7Zhiling Yang8Department of Pharmacy Hunan Provincial Peoples Hospital, (The First Affiliated Hospital of Hunan Normal University) Changsha ChinaDepartment of Pharmacy Hunan Provincial Peoples Hospital, (The First Affiliated Hospital of Hunan Normal University) Changsha ChinaDepartment of Pharmacy Hunan Provincial Peoples Hospital, (The First Affiliated Hospital of Hunan Normal University) Changsha ChinaDepartment of Pharmacy Hunan Provincial Peoples Hospital, (The First Affiliated Hospital of Hunan Normal University) Changsha ChinaDepartment of Pharmacy Hunan Provincial Peoples Hospital, (The First Affiliated Hospital of Hunan Normal University) Changsha ChinaDepartment of Pharmacy The Second Xiangya Hospital, Central South University Changsha ChinaShenzhen Wininnovate Bio‐Tech Co., Ltd Shenzhen ChinaDepartment of Pharmacy Hunan Provincial Peoples Hospital, (The First Affiliated Hospital of Hunan Normal University) Changsha ChinaDepartment of Pharmacy Hunan Provincial Peoples Hospital, (The First Affiliated Hospital of Hunan Normal University) Changsha ChinaAbstract Background and Aims Cardiac glycosides (CGs), traditionally used for heart failure, have shown potential as anti‐cancer agents. This study aims to explore their multifaceted mechanisms in cancer cell biology using proteome integral solubility alteration (PISA), focusing on the interaction with key proteins implicated in cellular metabolism and mitochondrial function. Methods We conducted lysate‐based and intact‐cell PISA assays on cancer cells treated with CGs (Digoxin, Digitoxin, Ouabain) to analyze protein solubility changes. This was followed by mass spectrometric analysis and bioinformatics to identify differentially soluble proteins (DSPs). Molecular docking simulations were performed to predict protein‐CG interactions. Public data including gene expression changes upon CG treatment were re‐analyzed for validation. Results The PISA assays revealed CGs’ broad‐spectrum interactions, particularly affecting proteins like PKM2, ANXA2, SLC16A1, GOT2 and GLUD1. Molecular docking confirmed stable interactions between CGs and these DSPs. Re‐analysis of public data supported the impact of CGs on cancer metabolism and cell signaling pathways. Conclusion Our findings suggest that CGs could be repurposed for cancer therapy by modulating cellular processes. The PISA data provide insights into the polypharmacological effects of CGs, warranting further exploration of their mechanisms and clinical potential.https://doi.org/10.1002/cam4.70252cardiac glycosidedigitoxindigoxindrug repositioningdrug repurposingoff‐target
spellingShingle Wenjie Qin
Yinhua Deng
Huan Ren
Yanling Liu
Ling Liu
Wenhui Liu
Yuxi Zhao
Chen Li
Zhiling Yang
Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
Cancer Medicine
cardiac glycoside
digitoxin
digoxin
drug repositioning
drug repurposing
off‐target
title Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
title_full Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
title_fullStr Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
title_full_unstemmed Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
title_short Exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
title_sort exploring the anticancer mechanism of cardiac glycosides using proteome integral solubility alteration approach
topic cardiac glycoside
digitoxin
digoxin
drug repositioning
drug repurposing
off‐target
url https://doi.org/10.1002/cam4.70252
work_keys_str_mv AT wenjieqin exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT yinhuadeng exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT huanren exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT yanlingliu exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT lingliu exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT wenhuiliu exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT yuxizhao exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT chenli exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach
AT zhilingyang exploringtheanticancermechanismofcardiacglycosidesusingproteomeintegralsolubilityalterationapproach